SL-401 Activity Against AML Blasts and Its Correlation With CD123 Levels
SL-401 Activity Against AML Blasts and Its Correlation With CD123 Levels. AACR 2015. Poster
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis
SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-triggered Myeloma Cell Growth and Prevents Osteoclastogenesis. ASH 2014. Poster
Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms
Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms. ASH 2014. Abstract
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia. ASH 2014. Abstract
SL-501, a Next-Generation Targeted Therapy Directed at the IL-3 Receptor, Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma
SL-501, a Next-Generation Targeted Therapy Directed at the IL-3 Receptor, Possesses Preclinical Anti-tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma. ASH 2014. Poster
SL-501, a Next-Generation Targeted Therapy Directed to IL-3R, Inhibits the Growth of Tyrosine Kinase Inhibitor-Resistant CML Cells
SL-501, a next-generation targeted therapy directed to IL-3R, inhibits the growth of tyrosine kinase inhibitor-resistant CML cells. AACR 2014. Abstract | Poster
Effect of a Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) on Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Osteolytic Bone Disease
Effect Of A Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) On Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth And Osteolytic Bone Disease. ASCO 2014. Abstract | Poster
Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma
Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma. SNO 2014. Poster
An Update on the Robust Clinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2013. Abstract | Poster
Preclinical Studies of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Preclinical Studies of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity in BPDCN Cell Lines, Primary Tumor, and in an In Vivo Model. ASH 2013. Abstract | Poster